New di(heteroaryl)thioethers 1,3-diarylureas in the thieno[3,2-b]pyridine series as VEGFR2 tyrosine kinase inhibitors: docking, synthesis, enzymatic and cellular assays
Artigo de Conferência
Visão geral
Visão geral
resumo
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is a tyrosine kinase receptor, expressed primarily in
endothelial cells, and is activated by the specific binding of VEGF, produced and released by the tumor, to the
VEGFR2 extracellular regulatory domain, undergoing autophosphorylation, triggering signaling pathways
leading to endothelial cell proliferation towards the tumor [!].Small molecules may act as inhibitors by
competing for the ATP-binding site of the VEGFR2 intracellular tyrosine kinase domain, thereby preventing the
intracellular signaling that leads to angiogenesis [2]. Herein, we report the synthesis using rational design of new
1-aryl-3-[3-thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas (la-c) as VEGFR2 tyrosine kinase inhibitors. The
compounds presented, with the arylurea in the meta position to the thioether and with F or a Me group, showed
very low !Cso values (11-28 nM) in enzymatic assays as predicted by molecular docking.
To examine the activity of compounds 1 in endothelial cells, VEGF-stimulated (60 ng/mL) Human Umbilical
Vein Endothelial Cells (HUVECs) were cultured in M199 medium in the absence (C) or presence of each
compound at different concentrations. A remarkable reduction in the proliferation of HUVECs using the BrdU
incorporation assay was observed for all compounds at I !JM, for compound la being observed a higher
antiproliferative effect. Further studies are ongoing to examine whether these molecules affect the expression
and activity of VEGFR2 and the signaling pathways, using western blotting assays. Given the established role of
VEGFR2 in proliferation and migration of endothelial cells, these molecules are promising anti-angiogenic
agents that can be used for therapeutic purposes in pathological conditions where angiogenesis is exacerbated,
such as cancer.
